Skip to main content
COLLEGIUM PHARMACEUTICAL, INC logo

COLLEGIUM PHARMACEUTICAL, INC — Investor Relations & Filings

Ticker · COLL ISIN · US19459J1043 LEI · 54930049FXZMTLW8D496 US Manufacturing
Open in API
Filings indexed 821 across all filing types
Latest filing 2016-05-11 Interim / Quarterly Rep…
Country US United States of America
Listing US COLL

About COLLEGIUM PHARMACEUTICAL, INC

https://www.collegiumpharma.com/

Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company that develops and commercializes medicines for people with serious medical conditions. The company is focused on building a portfolio of differentiated medications. Its primary area of expertise is in pain management, where it develops products with abuse-deterrent properties designed to be safer alternatives for patients and the community.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2016
2016-05-11 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 10, 2016, by Collegium Pharmaceutical, Inc. It specifically mentions Item 2.02, which relates to "Results of Operations and Financial Condition," and states that a press release announcing financial results for the quarterly period ended March 31, 2016, is attached as Exhibit 99.1. The document itself is a current report providing an update on quarterly financial results via a press release, not the full quarterly report or detailed financial statements. The length is 2918 characters, which is relatively short and consistent with a press release or earnings announcement rather than a full interim report. Therefore, this document is best classified as an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only.
2016-05-10 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a proxy statement or related materials filed pursuant to the Securities Exchange Act of 1934. It includes information about the annual shareholders' meeting, proposals to be voted on, and instructions for voting. The document is titled 'Definitive Additional Materials' related to the proxy statement, indicating it supplements the proxy materials rather than being the proxy statement itself. The content focuses on proxy solicitation and voting instructions rather than financial results or management discussion. Therefore, this document fits the category of Proxy Solicitation & Information Statement (PSI). The document length (7209 characters) and content confirm it is not a brief announcement or a full annual report but proxy-related materials.
2016-04-29 English
DEF 14A
Proxy Solicitation & Information Statement
2016-04-29 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 11, 2016, reporting the dismissal of the company's independent registered public accounting firm (Grant Thornton LLP) and the engagement of a new one (Deloitte & Touche LLP). It discusses audit-related matters, material weaknesses in internal controls, and includes a letter from the former auditor. The content focuses on audit firm changes and related disclosures rather than presenting full financial statements or a comprehensive audit report. The document is about audit-related information but is not a standalone audit report or full annual report. It is a regulatory filing reporting a significant event related to auditing. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (7799 characters) and detailed content support this classification with high confidence.
2016-04-15 English
PRIMARY DOCUMENT
Director's Dealing
2016-04-07 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.